Skip to main content

Advertisement

SpringerLink
Log in

Decade in review—hepatocellular carcinoma

HCC—subtypes, stratification and sorafenib

  • News & Views
  • Published:

From Nature Reviews Gastroenterology & Hepatology

View current issue Sign up to alerts

The past 10 years have represented a whirlwind of activity with regard to information on the risk factors, aetiopathogenesis, diagnosis and treatment of hepatocellular carcinoma. I will describe what I consider to be the major advances from both a tumour biology perspective and a clinical perspective over the past 10 years.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Future strategies for HCC diagnosis and treatment.

References

  1. Tanabe, K. K. et al. Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. JAMA 299, 53–60 (2008).

    Article  CAS  Google Scholar 

  2. Nault, J. C. et al. High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat. Commun. 4, 2218 (2013).

    Article  Google Scholar 

  3. Hoshida, Y. et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N. Engl. J. Med. 359, 1995–2004 (2008).

    Article  CAS  Google Scholar 

  4. Nault, J. C. et al. A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. Gastroenterology 145, 176–187 (2013).

    Article  CAS  Google Scholar 

  5. Govaere, O. et al. Keratin 19: a key role player in the invasion of human hepatocellular carcinomas. Gut 63, 674–685 (2014).

    Article  CAS  Google Scholar 

  6. Chen, C. J. et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295, 65–73 (2006).

    Article  CAS  Google Scholar 

  7. Forner, A. et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 47, 97–104 (2008).

    Article  Google Scholar 

  8. Memon, K. et al. Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times. Gastroenterology 141, 526–535 (2011).

    Article  Google Scholar 

  9. Mazzaferro, V. et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 10, 35–43 (2009).

    Article  Google Scholar 

  10. Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378–390 (2008).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by National Institute of Health Grant DK59427 and the Mayo Clinic.

Author information

Authors and Affiliations

  1. Division of Gastroenterology and Hepatology, Mayo College of Medicine, Mayo Clinic, 200 First Street SW, Rochester, 55905, MN, USA

    Gregory J. Gores

Authors
  1. Gregory J. Gores
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gregory J. Gores.

Ethics declarations

Competing interests

The author declares no competing financial interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gores, G. HCC—subtypes, stratification and sorafenib. Nat Rev Gastroenterol Hepatol 11, 645–647 (2014). https://doi.org/10.1038/nrgastro.2014.157

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrgastro.2014.157

  • Springer Nature Limited

This article is cited by

Search

Navigation